AngioDynamics (ANGO +2.3%) moves up after FQ2 earnings beat bottom line estimates by a penny on...

|By:, SA News Editor

AngioDynamics (ANGO +2.3%) moves up after FQ2 earnings beat bottom line estimates by a penny on an 89% Y/Y jump in vascular sales. Net profit slipped 15% Y/Y however, as higher input costs and expenses in its oncology division offset the sales gains. The company also lowered its FY13 revenue guidance to between $355M and $360M, down from its October view of revenue of $361M to $ 364M.